These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37309201)

  • 1. Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.
    Parisi R; Cowen EA; Gu S; Dusza S; Pulitzer M; Geyer MB; King AC; Markova A
    Leuk Lymphoma; 2023 Sep; 64(9):1583-1587. PubMed ID: 37309201
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC; Gökbuget N
    Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia.
    Lee BJ; Griffin SP; Doh J; Kongtim P; Chan A; O'Brien S; Jeyakumar D; Ciurea SO
    Am J Hematol; 2023 May; 98(5):E113-E115. PubMed ID: 36794446
    [No Abstract]   [Full Text] [Related]  

  • 6. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia.
    Filippidou M; Avgerinou G; Katsibardi K; Gavra M; Pons R; Kattamis A
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29040. PubMed ID: 33788389
    [No Abstract]   [Full Text] [Related]  

  • 8. Building a better blinatumomab.
    Litzow MR
    Am J Hematol; 2024 Apr; 99(4):512-514. PubMed ID: 38366135
    [No Abstract]   [Full Text] [Related]  

  • 9. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Horibe K; Morris JD; Tuglus CA; Dos Santos C; Kalabus J; Anderson A; Goto H; Ogawa C
    Int J Hematol; 2020 Aug; 112(2):223-233. PubMed ID: 32564243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is blinatumomab now standard of care consolidation for patients with ALL?
    Luger SM
    Clin Adv Hematol Oncol; 2023 Jun; 21(6):281-283. PubMed ID: 37530632
    [No Abstract]   [Full Text] [Related]  

  • 14. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
    van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
    N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).
    Friberg G; Reese D
    Ann Oncol; 2017 Aug; 28(8):2009-2012. PubMed ID: 28379283
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events.
    Klinger M; Zugmaier G; Nägele V; Goebeler ME; Brandl C; Stelljes M; Lassmann H; von Stackelberg A; Bargou RC; Kufer P
    Cancer Res; 2020 Jan; 80(1):91-101. PubMed ID: 31662326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis.
    Yu J; Wang W; Huang H
    Hematology; 2019 Dec; 24(1):199-207. PubMed ID: 30479190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinatumomab in Practice.
    Lantz J; Pham N; Jones C; Reed D; El Chaer F; Keng M
    Curr Hematol Malig Rep; 2024 Feb; 19(1):1-8. PubMed ID: 38060085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.